ESSA Pharma Presents Early Results from Clinical Trial Testing EPI-506 in End-stage Prostate Cancer

ESSA Pharma Presents Early Results from Clinical Trial Testing EPI-506 in End-stage Prostate Cancer
ESSA Pharma's small molecule androgen receptor inhibitor, EPI-506 (ralaniten acetate), has shown a favorable safety and tolerability profile among end-stage prostate cancer patients enrolled in a Phase 1/2 trial, as well as promising preliminary efficacy in higher-dose cohorts. Dr. Kim N. Chi, a prostate cancer expert at Vancouver's BC Cancer Agency, gave a poster presentation at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, held June 2-6 in Chicago. The study is titled "Efficacy, safety, tolerability and pharmacokinetics of EPI-506 (ralaniten acetate), a novel inhibitor of androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone." Phase 1 of the ongoing Phase 1/2 clinical trial (NCT02606123) evaluates the safety, pharmacology, dosing and anti-tumor activity of EPI-506 in 21 men with end-stage mCRPC, the lethal variant of the disease that develops even after castrate levels of testosterone. These patients had been unsuccessfully subjected to four or more prior therapies with Xtandi (enzalutamide) and/or Zytiga (abiraterone acetate), and had received a maximum of one line of chemotherapy. The men self-administered oral doses of EPI-506 ranging from 80 mg to 2400 mg, with mean drug exposure of 87 days. Of the 21 men, 17 discontinued treatment, mainly due to progression of the disease. Three have undergone extended treatment (with a median of 286 days), after scaling
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *